Pragmatic approaches to therapy for systemic lupus erythematosus

Nature Reviews Rheumatology

Volumn 10, Issue 2, 2014, Pages 97-107

  Xiong, Wen ^a   Lahita, Robert G ^a  

^a Cardiac Catheterization Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84895107356     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.157     Document Type: Review

References (156)

1. Sabahi, R. & Anolik, J. H. 2011;celltargeted therapy for systemic lupus erythematosus. Drugs 66, 1933-1948 (2006).
2. Jimenez, S., Cervera, R., Font, J. & Ingelmo, M. The epidemiology of systemic lupus erythematosus. Clin. Rev. Allergy Immunol. 25, 3-11 (2003).
3. FDA. Press release: FDA approves Benlysta to treat lupus. FDA [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246htm.
4. Gladman, D. D. & Urowitz, M. B. in Dubois' Lupus Erythematosus (eds Wallace, D. J. & Hahn, B. H) 1333-1353 (Lippincott, Williams & Wilkins, Philadelphia, 2007).
5. Ward, M. M., Pyun, E. & Studenski, S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch. Intern. Med. 156, 1337-1344 (1996).
6. Bertsias, G. et al. EULAR recommendations for the treatment of systemic lupus erythematosus: report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann. Rheum. Dis. 67, 195-205 (2008).
7. Gladman, D. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363-369 (1996).
8. Manzi, S. in Primer on the Rheumatic Diseases 13th edn (eds Klippel, J. H. et al.) 346-352 (Arthritis Foundation, 2008).
9. Formica, M. K., Palmer, J. R., Rosenberg, L. & McAlindon, T. E. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study. J. Rheumatol. 30, 1222-1226 (2003).
10. Ghaussy, N. O., Sibbitt, W. Jr, Bankhurst, A. D. & Qualls, C. R. Cigarette smoking and disease activity in systemic lupus erythematosus. J. Rheumatol. 30, 1215-1221 (2003).
11. Urowitz, M. B., Ibañez, D. & Gladman, D. D. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J. Rheumatol. 34, 70-75 (2007).
12. Hak, A. E., Karlson, E. W., Feskanich, D., Stampfer, M. J. & Costenbader, K. H. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum. 61, 1396-1402 (2009).
13. Bruce, I. N., Gladman, D. D. & Urowitz, M. B. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin. Exp. Rheumatol. 16, 435-440 (1998).
14. Wajed, J., Ahmad, Y., Durrington, P. N. & Bruce, I. N. Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatology (Oxford) 43, 7-12 (2004).
15. Bruce, I. N. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract. Res. Clin. Rheumatol. 19, 823-838 (2005).
16. Bruce, I. N., Urowitz, M. B., Gladman, D. D., Ibañez, D. & Steiner, G. S. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 48, 3159-3167 (2003).
17. Toloza, S. M. et al. Vitamin D insufficiency in a large female SLE cohort. Lupus 19, 13-19 (2010).
18. Almehed, K. et al. Prevalence and risk factors of osteoporosis in female SLE patients - extended report. Rheumatology (Oxford) 46, 1185-1190 (2007).
19. Panopalis, P. & Yazdany, J. Bone health in systemic lupus erythematosus. Curr. Rheumatol. Rep. 11, 177-184 (2009).
20. Ramsey-Goldman, R. et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 42, 882-890 (1999).
21. van Staa, T. P., Leufkens, H. G. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777-787 (2002).
22. Grossman, J. M. et al. American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 62, 1515-1526 (2010).
23. Jungers, P. et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum. 25, 618-623 (1982).
24. Petri, M. & Allbritton, J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J. Rheumatol. 19, 265-269 (1992).
25. Jeffries, M. et al. Sulpha allergy in lupus patients: a clinical perspective. Lupus 17, 202-205 (2008).
26. Sánchez-Guerrero, J. et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2539-2549 (2005).
27. Petri, M. et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2550-2558 (2005).
28. Julkunen, H. A., Kaaja, R. & Friman, C. Contraceptive practice in women with systemic lupus erythematosus. Br. J. Rheumatol. 32, 227-230 (1993).
29. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet. Gynecol. 107, 1453-1472 (2006).
30. Urbanus, R. T. et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 8, 998-1005 (2009).
31. Buyon, J. P. et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 142, 953-962 (2005).
32. Petri, M., Howard, D. & Repke, J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. 34, 1538-1545 (1991).
33. Ruiz-Irastorza, G. et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br. J. Rheumatol. 35, 133-138 (1996).
34. Yasmeen, S. et al. Pregnancy outcomes in women with systemic lupus erythematosus. J. Matern. Fetal Med. 10, 91-96 (2001).
35. Clowse, M. E. Lupus activity in pregnancy. Rheum. Dis. Clin. North Am. 33, 237-252 (2007).
36. Al-Herz, A., Schulzer, M. & Esdaile, J. M. Survey of antimalarial use in lupus pregnancy and lactation. J. Rheumatol. 29, 700-706 (2002).
37. Parke, A. L. & Rothfield, N. F. Antimalarial drugs in pregnancy - the North American experience. Lupus 5 (Suppl. 1), S67-S69 (1996).
38. Costedoat-Chalumeau, N. et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 48, 3207-3211 (2003).
39. Bermas, B. L. & Hill, J. A. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 38, 1722-1732 (1995).
40. Clowse, M. E., Magder, L. & Petri, M. Cyclophosphamide for lupus during pregnancy. Lupus 14, 593-597 (2005).
41. Gladman, D. & Urowitz, M. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 42, 1785-1796 (1999).
42. Lander, S. A., Wallace, D. J. & Weisman, M. H. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 11, 340-347 (2002).
43. D'Cruz, D. P., Khamashta, M. A. & Hughes, G. R. Systemic lupus erythematosus. Lancet 369, 587-596 (2007).
44. Sibilia, J. Treatment of systemic lupus erythematosus in 2 Joint Bone Spine 73, 591-598 (2006).
45. Sostres, C., Gargallo, C. J. & Arroyo, M. T. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol. 24, 121-132 (2010).
46. Horizon, A. A. & Wallace, D. J. Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin. Drug Saf. 3, 273-278 (2004).
47. Scheiman, J. M. & Hindley, C. E. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin. Ther. 32, 667-677 (2010).
48. Bhatt, D. L. et al. ACCF/ACG/AHA expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118, 1894-1909 (2008).
49. Kyburz, D., Brentano, F. & Gay, S. Mode of action of hydroxychloroquine in RA - evidence of an inhibitory effect on Toll-like receptor signaling. Nat. Clin. Pract. Rheumatol. 2, 458-459 (2006).
50. Petri, M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5 (Suppl. 1), S16 (1996).
51. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. & Khamashta, M. A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69, 20-28 (2010).
52. Fessler, B. J. et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52, 1473-1480 (2005).
53. Alarcon, G. S. et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66, 1168-1172 (2007).
54. Ruiz-Irastorza, G. et al. Effects of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577-583 (2006).
55. Jung, H., Bobba, R. & Su, J. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 62, 863-868 (2010).
56. Broder, A. & Putterman, C. The effects of hydroxychloroquine on antiphospholipid antibody titres in SLE. Ann. Rheum. Dis. 69, A10-A11 (2010).
57. Tam, L. S. et al. Effect of antimalarial agents of the fasting lipid profile in systemic lupus erythematosus. J. Rheumatol. 27, 2142-2145 (2000).
58. Borba, E. F. & Bonfá, E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol. 28, 780-785 (2001).
59. Lakshminarayanan, S., Walsh, S., Mohanraj, M. & Rothfield, N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J. Rheumatol. 28, 102-108 (2001).
60. Kalunian, K. & Merrill, J. T. New directions in the treatment of systemic lupus erythematosus. Curr. Med. Res. Opin. 6, 1501-1514 (2009).
61. Amissah-Arthur, M. B. & Gordon, C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther. Adv. Chronic Dis. 1, 163-175 (2010).
62. Tseng, C. E. et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54, 3623-3632 (2006).
63. Elbirt, D., Sthoeger, D., Asher, I. & Sthoeger, Z. M. The management of systemic lupus erythematosus: facts and controversies. Clin. Dermatol. 28, 330-336 (2010).
64. Parker, B. J. & Bruce, I. N. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 16, 387-393 (2007).
65. Recommendation for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology ad hoc committee on glucocorticoid-induced osteoporosis. Arthritis Rheum. 44, 1496-1503 (2001).
66. Chan, E. S. & Cronstein, B. N. Methotrexate - how does it really work? Nat. Rev. Rheumatol. 6, 175-178 (2010).
67. Carneiro, J. R. & Sato, E. I. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J. Rheumatol. 26, 1275-1279 (1999).
68. Fortin, P. R. et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 59, 1796-1804 (2008).
69. Islam, N. et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int. J. Rheum. Dis. 15, 62-68 (2012).
70. Swaak, A. J. et al. Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study. Clin. Rheumatol. 3, 285-291 (1984).
71. Contreras, G. et al. Sequential therapy for proliferative lupus nephritis. N. Engl. J. Med. 350, 971-980 (2004).
72. Manzi, S. in Primer on the Rheumatic Diseases (eds Kippel, J. H. et al.) 346-352 (The Arthritis Foundation, Atlanta, 2001).
73. Becker, H., Potyka, P., Weber, C., Renelt, M. & Federlin, K. Thelper cell subsets in patients with inflammatory rheumatic diseases undergoing immunosuppressive therapy. Immun. Infekt. 19, 26-27 (1991).
74. Petri, M., Jones, R. J. & Brodsky, R. A. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 48, 166-173 (2003).
75. Petri, M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 13, 366-371 (2004).
76. Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121-2131 (2002).
77. Houssiau, F. A. et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61-64 (2010).
78. Monach, P. A., Arnold, L. M. & Merkel, P. A. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 62, 9-21 (2010).
79. Somers, E. C. et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 52, 2761-2767 (2005).
80. Ginzler, E. M. & Aranow, C. Mycophenolate mofetil in lupus nephritis. Lupus 14, 59-64 (2005).
81. Mak, A. et al. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 48, 944-952 (2009).
82. Kamanamool, N. et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis. Medicine 89, 227-235 (2010).
83. Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886-1895 (2011).
84. Pisoni, C. N. et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J. Rheumatol. 32, 1047-1052 (2005).
85. Baker, K. P. et al. Generation and characterization of LymphoStatB, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253-3265 (2003).
86. Houssiau, F. A. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69, 2083-2089 (2010).
87. Hahn, B. H. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64, 797-808 (2012).
88. Xiong, W. & Lahita, R. Novel treatments for systemic lupus erythematosus. Ther. Adv. Musculoskelet Dis. 3, 255-266 (2011).
89. Yoo, D. H. Anticytokine therapy in systemic lupus erythematosus. Lupus 19, 1460-1467 (2010).
90. Yildirim-Toruner, C. & Diamond, B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J. Allergy Clin. Immunol. 127, 303-312 (2011).
91. Bezalel, S., Asher, I., Elbirt, D. & Sthoeger, Z. M. Novel biological treatments for systemic lupus erythematosus: current and future modalities. Isr. Med. Assoc. J. 14, 508-514 (2012).
92. Human Genome Sciences. Arthritis Advisory Committee Meeting briefing document for the 16 November meeting. FDA [online], http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ArthritisDrugsAdvisoryCommittee/UCM233pdf (2010).
93. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731 (2011).
94. Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918-3930 (2011).
95. Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).
96. Ramos-Casals, M., Sanz, I., Bosch, X., Stone, J. H. & Khamashta, M. A. 2011;celldepleting therapy in systemic lupus erythematosus. Am. J. Med. 125, 327-336 (2012).
97. Wallace, D. J. et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with active systemic lupus erythematosus. Lupus 22, 144-154 (2013).
98. Cheema, G. S., Roschke, V., Hilbert, D. M. & Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44, 1313-1319 (2001).
99. Furie, R. et al. Biologic activity and safety of belimumab, a neutralizing anti2011;lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res. Ther. 10, R109 (2008).
100. Karim, M. Y., Pisoni, C. N. & Khamashta, M. A. Update on immunotherapy for systemic lupus erythematosus - what's hot and what's not! Rheumatology (Oxford) 48, 332-341 (2009).
101. Lu, T. Y. et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61, 482-487 (2009).
102. Ramos-Casals, M., Soto, M. J., Cuadrado, M. J. & Khamashta, M. A. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18, 767-776 (2009).
103. Turner-Stokes, T. et al. The efficacy of repeated treatment with 2011;cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 50, 1401-1408 (2011).
104. Terrier, B. et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62, 2458-2466 (2010).
105. Merrill, J. et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 20, 709-716 (2011).
106. Furie, R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 60 (Suppl. 1), S429 (2009).
107. Arnal, C. et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J. Rheumatol. 29, 75-83 (2002).
108. Levy, Y. et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 8, 705-712 (1999).
109. Milstone, A. M., Meyers, K. & Elia, J. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin. Rheumatol. 24, 394-397 (2005).
110. Micheloud, D., Calderon, M., Caparrros, M. & D'Cruz, D. P. Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann. Rheum. Dis. 66, 986-987 (2007).
111. Lazurova, I. et al. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. Clin. Rheumatol. 26, 2145-2147 (2007).
112. Lesprit, P. et al. Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin. Scand. J. Rheumatol. 25, 177-179 (1996).
113. Aharon, A. et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 6, 408-411 (1997).
114. Chetan, G., Mahadevan, S., Sulanthung, K. & Narayanan, P. Intravenous immunoglobulin therapy of lupus pneumonitis. Indian J. Pediatr. 74, 1032-1033 (2007).
115. Levy, Y. et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin. Arthritis Rheum. 29, 321-327 (2000).
116. Papo, T. et al. The sprectrum of reactive hemophagocytic syndrome in systemic lupus erythematosus. J. Rheumatol. 26, 927-930 (1999).
117. Hahn, B. H. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64, 797-808 (2012).
118. Dooley, M. A., Aranow, C. & Ginzler, E. M. Review of ACR renal criteria in systemic lupus erythematosus. Lupus 13, 857-860 (2004).
119. Kasitanon, N., Magder, L. S. & Petri, M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85, 147-156 (2006).
120. Alarcon, G. S. et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 11, 95-101 (2002).
121. Bernatsky, S. et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550-2557 (2006).
122. Cervera, R. et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82, 299-308 (2003).
123. Kaplan, A. A. & George, J. N. Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults. UpToDate [online], http://www.uptodate.com/contents/ treatmentofthromboticthrombocytopenicpurpurahemolyticuremicsyndromein-adults (2011).
124. Jennekens, F. G. & Kater, L. The central nervous system in systemic lupus erythematosus. Part 1: clinical syndromes: a literature investigation. Rheumatology (Oxford) 41, 605-618 (2002).
125. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 42, 599-608 (1999).
126. Bonfa, E. et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N. Engl. J. Med. 317, 265-271 (1987).
127. Isshi, K. & Hirohata, S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 39, 1483-1490 (1996).
128. Carbotte, R. M., Denburg, S. D. & Denburg, J. A. Cognitive deficit associated with rheumatic diseases: neuropsychological perspectives. Arthritis Rheum. 38, 1363-1374 (1995).
129. Hanly, J. G., Hong, C., Smith, S. & Fisk, J. D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 42, 728-734 (1999).
130. Omdal, R. et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 12, 392-398 (2005).
131. Conti, F. et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for antiendothelialcell antibodies. Arthritis Res. Ther. 6, R366-R372 (2004).
132. Lapteva, L. et al. AntiNmethylDaspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54, 2505-2514 (2006).
133. Harrison, M. J., Ravdin, L. D. & Lockshin, M. D. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum. 54, 2515-2522 (2006).
134. McLaurin, E. Y., Holliday, S. L., Williams, P. & Brey, R. L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64, 297-303 (2005).
135. Schroeder, J. O., Euler, H. H. & Löffler, H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann. Intern. Med. 107, 344-346 (1987).
136. Neuwelt, C. M. et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med. 98, 32-41 (1995).
137. Boumpas, D. T. et al. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q. J. Med. 81, 975-984 (1991).
138. Mok, C. C., Lau, C. S. & Wong, R. W. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am. J. Med. 115, 59-62 (2003).
139. Roenigk, H. H. Jr, Martin, J. S., Eichorn, P. & Gilliam, J. N. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 25, 281-285 (1980).
140. Jessop, S., Whitelaw, D. A. & Delamere, F. M. Drugs for discoid lupus erythematosus. Cochrane Database Syst. Rev. CD002954 (2009).
141. Kuhn, A. et al. Efficacy of tacrolimus % ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J. Am. Acad. Dermatol. 65, 54-64 (2011).
142. Tzung, T. Y., Liu, Y. S. & Chang, H. W. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br. J. Dermatol. 156, 191-192 (2007).
143. Gunasekera, V. et al. Refractory discoid lupus erythematosis of the eyelid successfully treated with intra-lesional triamcinolone. Eye (Lond.) 22, 1205-1206 (2008).
144. Ruzicka, T. et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br. J. Dermatol. 127, 513-518 (1992).
145. Chang, A. Y. et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch. Dermatol. 147, 1261-1267 (2011).
146. Carneiro, J. R. & Sato, E. I. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J. Rheumatol. 26, 1275-1279 (1999).
147. Newton, R. C. et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch. Dermatol. 122, 170-176 (1986).
148. Kreuter, A. et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br. J. Dermatol. 156, 1321-1327 (2007).
149. Gammon, B., Hansen, C. & Costner, M. I. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 65, 717-721 (2011).
150. Lindskov, R. & Reymann, F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 172, 214-217 (1986).
151. Braunstein, I. et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J. Am. Acad. Dermatol. 66, 571-582 (2012).
152. Cortés-Hernández, J., Avila, G., Vilardell-Tarrés, M. & Ordi-Ros, J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res. Ther. 14, R265 (2012).
153. Goodfield, M., Davison, K. & Bowden, K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J. Dermatolog. Treat. 15, 46-50 (2004).
154. Mamula, M. J., Fatenejad, S. & Craft, J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J. Immunol. 152, 1453-1461 (1994).
155. Martin, F. & Chan, A. C. B cell immunobiology in disease: evolving concepts from the clinic. Ann. Rev. Immunol. 24, 467-496 (2006).
156. Boule, M. W. et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199, 1631-1640 (2004).